AR067555A1 - Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal - Google Patents
Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminalInfo
- Publication number
- AR067555A1 AR067555A1 ARP080103043A ARP080103043A AR067555A1 AR 067555 A1 AR067555 A1 AR 067555A1 AR P080103043 A ARP080103043 A AR P080103043A AR P080103043 A ARP080103043 A AR P080103043A AR 067555 A1 AR067555 A1 AR 067555A1
- Authority
- AR
- Argentina
- Prior art keywords
- insulinotropic peptide
- insulinotropic
- derivatives
- derivative
- amino acid
- Prior art date
Links
- 230000002473 insulinotropic effect Effects 0.000 title abstract 12
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 150000001413 amino acids Chemical group 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108010011459 Exenatide Proteins 0.000 abstract 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- -1 dimethyl-histidyl Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
- 108010015174 exendin 3 Proteins 0.000 abstract 1
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 abstract 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un derivado de péptido insulinotropico, con actividad insulinotropica y estabilidad en sangre mejoradas, y una composicion farmacéutica para el tratamiento de la diabetes, que comprende derivados de péptidos insulinotropicos. En particular, se caracteriza por un péptido insulinotropico modificado con aminoácido N-terminal. Los derivados de péptidos insulinotropicos de la presente solicitud exhiben efectos terapéuticos, que no se observan en análogos nativos y en otros análogos de péptidos insulinotropicos. Por lo tanto, se pueden proporcionar eficazmente derivados de péptidos insulinotropicos y la composicion farmacéutica que los comprende para el tratamiento de las enfermedades. Reivindicacion 1: Un derivado de péptido insulinotropico caracterizado porque el residuo de histidina N-terminal del péptido insulinotropico está sustituido con material seleccionado del grupo que comprende desaminohistidilo, dimetil-histidilo, beta-hidroxi imidazopropionilo, 4-imidazoacetilo y beta-carboxi imidazopropionilo. Reivindicacion 2: El derivado de péptido insulinotropico de acuerdo con la reivindicacion 1, caracterizado porque el péptido insulinotropico se selecciona del grupo que comprende exendina-3, exendina-4 y sus derivados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20070071071 | 2007-07-16 | ||
| US99115507P | 2007-11-29 | 2007-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067555A1 true AR067555A1 (es) | 2009-10-14 |
Family
ID=40260219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103043A AR067555A1 (es) | 2007-07-16 | 2008-07-16 | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9422349B2 (es) |
| EP (4) | EP2537860B1 (es) |
| JP (7) | JP2009019027A (es) |
| KR (1) | KR101231431B1 (es) |
| CN (2) | CN101778863A (es) |
| AR (1) | AR067555A1 (es) |
| AU (1) | AU2008276762A1 (es) |
| BR (1) | BRPI0814097A8 (es) |
| CA (3) | CA2789123C (es) |
| DK (1) | DK2390265T3 (es) |
| ES (3) | ES2444622T3 (es) |
| IL (1) | IL203288A (es) |
| MY (1) | MY167486A (es) |
| NZ (3) | NZ582471A (es) |
| PH (2) | PH12014500923A1 (es) |
| PT (1) | PT2390265E (es) |
| RU (1) | RU2442792C2 (es) |
| SG (3) | SG10201510245SA (es) |
| TW (3) | TWI524896B (es) |
| WO (1) | WO2009011544A2 (es) |
| ZA (1) | ZA201000125B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009019027A (ja) * | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
| PL2408800T3 (pl) * | 2009-03-20 | 2016-11-30 | Sposób wytwarzania koniugatu miejscowo-specyficznego, fizjologicznie aktywnego polipeptydu | |
| AU2010321587A1 (en) | 2009-11-23 | 2012-06-07 | Amylin Pharmaceuticals, Inc. | Polypeptide Conjugate |
| RU2422461C1 (ru) * | 2010-02-09 | 2011-06-27 | Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет | Аналоги эксенатида |
| KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| JP6174489B2 (ja) | 2010-09-28 | 2017-08-02 | アエゲリオン ファーマシューティカルズ，インコーポレイテッド | 高可溶性レプチン |
| CN106986940A (zh) | 2010-09-28 | 2017-07-28 | 艾米琳制药有限责任公司 | 具有增强的作用持续时间的工程化多肽 |
| US20140221282A1 (en) | 2011-05-25 | 2014-08-07 | Astrazeneca Pharmaceuticals Lp | Long duration dual hormone conjugates |
| UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| US9382304B2 (en) | 2011-07-08 | 2016-07-05 | Amylin Pharmaceuticals, Llc | Engineered polypeptides having enhanced duration of action with reduced immunogenicity |
| DK2729160T3 (da) | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| CN103130889A (zh) * | 2012-06-15 | 2013-06-05 | 中国药科大学 | 一种Exendin-4类似物及其制备方法和应用 |
| US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
| AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| KR20140088837A (ko) * | 2013-01-03 | 2014-07-11 | 한미약품 주식회사 | Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체 |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| AR096890A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
| MA43289B1 (fr) | 2014-01-20 | 2019-12-31 | Hanmi Pharm Ind Co Ltd | Insuline à action prolongée et utilisation associée |
| EA201691795A1 (ru) | 2014-03-31 | 2017-03-31 | Ханми Фарм. Ко., Лтд. | Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| US11123436B2 (en) | 2015-07-24 | 2021-09-21 | Hanmi Pharm. Co., Ltd. | Method of preparing physiologically active polypeptide conjugate |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| BR112018008681A2 (pt) * | 2015-10-28 | 2018-10-30 | Tufts Medical Center | novos polipeptídeos com estabilidade proteolítica melhorada, e métodos para preparar e usar os mesmos |
| BR112019005637A2 (pt) | 2016-09-23 | 2019-07-30 | Hanmi Pharm Ind Co Ltd | análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso |
| EP3549950A4 (en) | 2016-12-05 | 2020-08-19 | Hanmi Pharm. Co., Ltd. | CONJUGATE WITH MITIGATED IMMUNE RESPONSE |
| JP2020506932A (ja) | 2017-02-03 | 2020-03-05 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続性が増加した生理活性物質の結合体及びその用途 |
| TWI798209B (zh) | 2017-03-23 | 2023-04-11 | 南韓商韓美藥品股份有限公司 | 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途 |
| US20240299500A1 (en) * | 2020-12-24 | 2024-09-12 | Hanmi Pharm Co., Ltd. | Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome |
| WO2022266467A2 (en) | 2021-06-17 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Recombinant histone polypeptide and uses thereof |
| KR20230000682A (ko) | 2021-06-25 | 2023-01-03 | 한미약품 주식회사 | 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드 |
| KR20230010571A (ko) | 2021-07-12 | 2023-01-19 | 한미약품 주식회사 | Glp-1 유사체를 함유하는 경구 투여 제형 조성물 |
| EP4504760A1 (en) * | 2022-04-08 | 2025-02-12 | Danmarks Tekniske Universitet | Histidine methyltransferase for increased peptide and protein stability |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7A (en) * | 1836-08-10 | Thomas Blanchard | Machine for boring holes and cutting lanyard-scores in deadeyes | |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5424686A (en) | 1994-04-20 | 1995-06-13 | Philips Electronics North America Corporation | Negative-resistance-compensated microwave buffer |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| JP2000516912A (ja) | 1996-06-05 | 2000-12-19 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | エキセンジン類似体、それらの製造方法およびそれらを含有する製剤 |
| US7235627B2 (en) | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| KR100556067B1 (ko) * | 1996-08-30 | 2006-03-07 | 노보 노르디스크 에이/에스 | 지엘피 - 1 유도체 |
| JP2002507188A (ja) | 1996-08-30 | 2002-03-05 | イーライ・リリー・アンド・カンパニー | グルカゴン様ペプチド―１（ｇｌｐ―１）またはその同族体における外科処置後の異化変調を防止するための使用 |
| AU739020B2 (en) | 1997-01-07 | 2001-10-04 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
| EP1938831A1 (en) | 1997-08-08 | 2008-07-02 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| PT1019077E (pt) | 1997-08-08 | 2008-02-21 | Amylin Pharmaceuticals Inc | Novos compostos agonistas de exendina |
| US7157555B1 (en) * | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| US7220721B1 (en) * | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
| US6703359B1 (en) * | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
| EP1056775B1 (en) * | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| CZ2001690A3 (cs) | 1998-08-28 | 2002-04-17 | Eli Lilly And Company | Způsob podávání inzulinotropních peptidů |
| BR0116024A (pt) | 2000-12-07 | 2005-12-13 | Lilly Co Eli | Proteìna de fusão heteróloga e uso da mesma |
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| US6573237B2 (en) * | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
| JP4417113B2 (ja) | 2002-02-20 | 2010-02-17 | エミスフェアー・テクノロジーズ・インク | Ｇｌｐ−１分子の投与方法 |
| AU2003268621B2 (en) * | 2002-10-02 | 2009-01-15 | Zealand Pharma A/S | Stabilized exendin-4 compounds |
| JP2006514035A (ja) * | 2002-12-17 | 2006-04-27 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 心不整脈の予防および治療 |
| US7790681B2 (en) * | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
| JP2006514649A (ja) * | 2003-12-17 | 2006-05-11 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 腎症の治療および予防のための組成物 |
| TW200611704A (en) | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
| BRPI0608516A2 (pt) * | 2005-03-18 | 2010-11-16 | Novo Nordisk As | análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto |
| DK2347762T3 (da) * | 2005-08-19 | 2019-06-11 | Amylin Pharmaceuticals Llc | Exendin til behandling af diabetes og reduktion af kropsvægt |
| EP1961764B1 (en) | 2005-11-30 | 2011-05-11 | Shionogi Co., Ltd. | Sugar chain adduct of peptide and pharmaceutical comprising the same as active ingredient |
| US8501693B2 (en) * | 2006-08-04 | 2013-08-06 | Amylin Pharmaceuticals, Llc | Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| WO2008145721A2 (en) * | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | N-terminal modification of polypeptides for protection against degradation by aminopeptidases |
| JP2009019027A (ja) * | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
| US9816387B2 (en) | 2014-09-09 | 2017-11-14 | United Technologies Corporation | Attachment faces for clamped turbine stator of a gas turbine engine |
-
2007
- 2007-10-03 JP JP2007259853A patent/JP2009019027A/ja active Pending
-
2008
- 2008-07-16 SG SG10201510245SA patent/SG10201510245SA/en unknown
- 2008-07-16 CA CA2789123A patent/CA2789123C/en active Active
- 2008-07-16 JP JP2010516925A patent/JP5481377B2/ja active Active
- 2008-07-16 RU RU2010101232/10A patent/RU2442792C2/ru active
- 2008-07-16 KR KR1020080069234A patent/KR101231431B1/ko active Active
- 2008-07-16 ES ES11162132.2T patent/ES2444622T3/es active Active
- 2008-07-16 CA CA2789112A patent/CA2789112C/en active Active
- 2008-07-16 NZ NZ582471A patent/NZ582471A/en unknown
- 2008-07-16 CA CA2693154A patent/CA2693154C/en active Active
- 2008-07-16 TW TW101140652A patent/TWI524896B/zh active
- 2008-07-16 AR ARP080103043A patent/AR067555A1/es active IP Right Grant
- 2008-07-16 ES ES12185376.6T patent/ES2528347T3/es active Active
- 2008-07-16 MY MYPI2010000187A patent/MY167486A/en unknown
- 2008-07-16 US US12/669,372 patent/US9422349B2/en active Active
- 2008-07-16 EP EP12185370.9A patent/EP2537860B1/en active Active
- 2008-07-16 NZ NZ596828A patent/NZ596828A/en unknown
- 2008-07-16 EP EP12185376.6A patent/EP2537861B1/en active Active
- 2008-07-16 BR BRPI0814097A patent/BRPI0814097A8/pt not_active Application Discontinuation
- 2008-07-16 NZ NZ594853A patent/NZ594853A/en unknown
- 2008-07-16 AU AU2008276762A patent/AU2008276762A1/en not_active Abandoned
- 2008-07-16 WO PCT/KR2008/004170 patent/WO2009011544A2/en not_active Ceased
- 2008-07-16 EP EP08778827A patent/EP2176289A4/en not_active Withdrawn
- 2008-07-16 CN CN200880024892A patent/CN101778863A/zh active Pending
- 2008-07-16 TW TW101140650A patent/TWI532496B/zh active
- 2008-07-16 DK DK11162132.2T patent/DK2390265T3/da active
- 2008-07-16 ES ES12185370.9T patent/ES2528346T3/es active Active
- 2008-07-16 PT PT111621322T patent/PT2390265E/pt unknown
- 2008-07-16 CN CN201510053063.8A patent/CN104672319B/zh active Active
- 2008-07-16 TW TW097126905A patent/TWI454276B/zh active
- 2008-07-16 SG SG10201510249PA patent/SG10201510249PA/en unknown
- 2008-07-16 EP EP11162132.2A patent/EP2390265B1/en active Active
- 2008-07-16 SG SG2012052114A patent/SG183033A1/en unknown
-
2010
- 2010-01-07 ZA ZA2010/00125A patent/ZA201000125B/en unknown
- 2010-01-13 IL IL203288A patent/IL203288A/en active IP Right Grant
-
2012
- 2012-09-03 JP JP2012193520A patent/JP6023515B2/ja active Active
- 2012-09-03 JP JP2012193521A patent/JP6023516B2/ja active Active
-
2013
- 2013-12-20 JP JP2013264258A patent/JP2014094948A/ja active Pending
-
2014
- 2014-04-25 PH PH12014500923A patent/PH12014500923A1/en unknown
- 2014-04-25 PH PH12014500922A patent/PH12014500922A1/en unknown
-
2015
- 2015-05-07 JP JP2015095154A patent/JP2015172058A/ja not_active Withdrawn
- 2015-05-07 JP JP2015095145A patent/JP2015166368A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| CL2020002574A1 (es) | Análogos novedosos de glp-1 | |
| PE20170087A1 (es) | Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| AR099975A1 (es) | Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| PE20090932A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 | |
| CL2012001722A1 (es) | Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes. | |
| CO7400885A2 (es) | Análogos de glucagón | |
| AR092873A1 (es) | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon | |
| DOP2010000209A (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
| CL2009001340A1 (es) | Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto. | |
| AR070119A1 (es) | Derivados de insulina con perfil tiempo / accion extremadamente retardado | |
| GT201200263A (es) | "nuevos peptidos y metodos para su preparacion y uso" | |
| AR110300A1 (es) | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip | |
| PE20151770A1 (es) | Compuesto peptidico | |
| AR110301A1 (es) | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip | |
| PE20191716A1 (es) | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos | |
| BR112022023834A2 (pt) | Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo | |
| AR081339A1 (es) | Conjugados peptidicos | |
| MX2016001971A (es) | Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos. | |
| AR094180A1 (es) | Derivados de exendina-4 | |
| PE20221518A1 (es) | Analogos de incretina y sus usos | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| MX380191B (es) | Combinaciones de modalidades para el tratamiento de la diabetes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |